Biomarin Pharmaceutical (BMRN) Research & Development (2009 - 2026)

Biomarin Pharmaceutical has disclosed Research & Development across 18 years of filings, most recently posting $178.8 million for Q1 2026.

• Quarterly Research & Development rose 12.64% year-over-year to $178.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $942.0 million (up 34.39% YoY) and the FY2025 annual result came in at $921.9 million, up 23.39% from the prior year.
• Research & Development eased to $178.8 million in Q1 2026, from $192.4 million in the prior quarter.
• Over five years, Research & Development peaked at $409.5 million in Q3 2025 and troughed at $157.8 million in Q3 2022.
• A 5-year average of $190.8 million and a median of $177.4 million in 2023 frame the typical range for Research & Development.
• Biggest YoY gain for Research & Development was 121.46% in 2025; the steepest drop was 22.57% in 2025.
• Tracing BMRN's Research & Development over 5 years: stood at $172.8 million in 2022, then rose by 19.39% to $206.2 million in 2023, then decreased by 15.87% to $173.5 million in 2024, then rose by 10.9% to $192.4 million in 2025, then slipped by 7.08% to $178.8 million in 2026.
• Business Quant data shows BMRN's Research & Development at $178.8 million in Q1 2026, $192.4 million in Q4 2025, and $409.5 million in Q3 2025.